DeepCure discovers transformative small molecule therapies for immune and inflammatory diseases. The company uses a chemistry platform that combines AI, physics-based tools and automated chemical synthesis to identify truly novel molecules that address unsolved challenges in drug discovery. The pipeline includes an oral STAT6 program with multiple novel scaffolds and an oral BRD4(BD2) program with the first truly selective inhibitor. DeepCure expects to start in clinical trials in 2025.
Company Details
- Employees
- 34
- Founded
- -
- Address
- 100 City Hall Plaza, 5,
- in****@****cure.ai
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- deepcure.ai
- Keywords
- Chemistry, Immunology, Pharmaceuticals, Biotechnology, ArtificialIntelligence, DrugDiscovery.
- HQ
- Boston, MA
Deepcure Questions
Deepcure's website is deepcure.ai
Deepcure's LinkedIn profile is https://www.linkedin.com/company/deepcure
Deepcure has
34 employees.
View email and phone details for 34
employees at Deepcure.
Deepcure's industry is
Biotechnology Research
Deepcure's top competitors are
Evogene,
Cytoreason,
Anima Biotech,
Imagene,
Protai,
Memed,
Aidoc,
Neurokaire (Formerly Genetika+),
Nucleai,
Immunai.
Deepcure's support email address is info@deepcure.ai
Deepcure's categories are Biotechnology Research
Deepcure's founding year is 2018
